Clinical trials: Schizophrenia and Disorders With Psychotic Features
Schizophrenia
A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia
A Phase 3, Multicenter, Two-part Study with a 5-week Double-blind Part (Randomized, Parallel-group, Placebo-controlled) followed by a 12-week Open-label Extension Part, to Evaluate the Efficacy and Safety of KarXT in Acutely…
- Trial name
- UNITE-001 (NCT05919823)
- Testing
- Xanomeline and Trospium Chloride Capsules
- Where
- 28 sites in China
- Volunteers
- 202 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophrenia Spectrum, Schizophrenia
The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain
Antipsychotic-induced metabolic disturbances, especially weight gain, are common in patients with schizophrenia. There are no hitherto effective treatments for reducing antipsychotic-induced weight gain.
- Conditions
- Schizophrenia Spectrum, Schizophrenia, Antipsychotic Induced Weight Gain
- Trial name
- dTMS (NCT07795554)
- Testing
- dTMS of accelerated intermittent theta burst stimulation, ACC-iTBS
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Second Xiangya Hospital of Central South University
Schizophrenia
Positron Emission Tomagraphy (PET) Study Following a Single Oral Dose of OPC-34712
Determine the degree of striatal D2 receptor occupancy induced by OPC-34712 at differenht dose levels in healthy volunteers.
- Trial name
- NCT00805454
- Testing
- OPC-34712
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
20110165: Study to Evaluate the Effect of AMG 747 on Schizophrenia Negative Symptoms (Study 165)
The purpose of this study is to evaluate the effect of AMG 747 on negative symptoms of schizophrenia in patients who are stable on current antipsychotic treatment.
- Trial name
- NCT01568229
- Testing
- AMG 747
- Where
- 44 sites in United States, Czechia and 4 more
- Volunteers
- 111 people
- Sponsor
- Amgen
Mental Illness, Schizophrenia
Measuring Beliefs and Norms About Persons With Mental Illness
Survey experiment to estimate drivers of mental illness stigma
- Conditions
- Mental Illness, Schizophrenia, Bipolar Disorder, Depression
- Trial name
- NCT03656770
- Testing
- Survey questionnaire
- Where
- Uganda
- Volunteers
- 1,782 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Severe Mental Illness, Rehabilitation
Using Clinical Process Indicators, Patient Reported Outcome Measures (PROMs), and Patient Reported Experience Measures (PREMs) to Improve the Quality and Continuity of Care for Psychiatric Patients
The objective of the proposed study is to take a further step in this direction by developing, implementing and monitoring a routine systematic evaluation of clinical process and outcome indicators, patient reported experience…
- Conditions
- Severe Mental Illness, Rehabilitation, Schizophrenia
- Trial name
- PROM-PREM (NCT04314154)
- Testing
- Monitoring PROM @ PREM data on participating patients
- Where
- Israel
- Volunteers
- 125 people
- Sponsor
- Shalvata Mental Health Center
Schizophrenia, Schizoaffective Disorder
A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder
The purpose of this study is to evaluate the efficacy and safety of ziprasidone in acute exacerbation of schizophrenia or schizoaffective disorder, including patients with recent onset of symptoms
- Trial name
- NCT00645229
- Testing
- Ziprasidone
- Where
- Portugal
- Volunteers
- 1 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Schizophrenia, Psychotic Disorders
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
This is a randomized, single-dose, open-label, parallel-group study. Patients will undergo the screening evaluations to determine eligibility within 28 days prior to study drug administration.
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders
- Trial name
- NCT05321602
- Testing
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid
- Where
- 9 sites in United States
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Psychotic Disorders
Investigation of Objective Cognitive Effort in Neuropsychological Evaluation of Psychotic Disorders
Psychotic disorders are characterised by a heterogeneity of symptoms, including cognitive disorders, which predict functional outcome. To date, the evaluation of cognitive functions essentially measures performance.
- Conditions
- Schizophrenia, Psychotic Disorders, Cognitive Impairment, Motivation
- Trial name
- INVESTIGECCO (NCT06782672)
- Testing
- Cardiovascular measurements, Experimental memory task, Questionnaire and semi-structured psychological interview
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Psychosis, Schizophrenia
Goals in Focus: CBT for Motivational Negative Symptoms of Psychosis
This pilot feasibility trial aims to evaluate the "Goals in Focus" intervention for motivational negative symptoms in people with psychosis.
- Conditions
- Psychosis, Schizophrenia, Negative Symptoms With Primary Psychotic Disorder
- Trial name
- GIF (NCT05252039)
- Testing
- Goals in Focus
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- University of Hamburg-Eppendorf
Schizophrenia, Latent Schizophrenia
A Psychopathological Study of Latent (Early) Schizophrenia: Clinical Pathology/Neuropsychological Dysfunctions
Current diagnostic criteria of schizophrenia are based on marked positive and negative symptoms. This definition may impede the exploration of basic phenomenological psychopathology or pathological mechanism of schizophrenia.
- Trial name
- NCT00155519
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Schizophrenia
Effects of Eszopiclone on Sleep and Memory in Schizophrenia
The investigators will test the hypothesis that the sleep medication, eszopiclone, can normalize brain activity during sleep and improve memory in patients with schizophrenia.
- Trial name
- NCT01641900
- Testing
- eszopiclone
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Schizophrenia
Assessment of Schizophrenia Patients' Clinical Study Experiences
The study seeks to delve into the firsthand experiences of patients diagnosed with schizophrenia who partake in a separate clinical trial featuring a specific medical intervention.
- Trial name
- NCT05948111
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Schizophrenia, Schizoaffective Disorder
Prebiotic Treatment in People With Schizophrenia - Pilot Study
The purpose of this study is to examine changes in serum butyrate levels with the prebiotic: Prebiotin (12g/day), an oligofructose-enriched inulin (OEI); the effect of OEI on the composition of the gastrointestinal microbiota in…
- Trial name
- preFOCIS (NCT03617783)
- Testing
- Prebiotin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Maryland, Baltimore
Schizophrenia
Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
This study will be conducted to evaluate the efficacy, safety, and tolerability of GWP42003-P versus placebo in participants with schizophrenia experiencing inadequate response to ongoing antipsychotic treatment.
- Trial name
- NCT04421456
- Testing
- GWP42003-P
- Where
- 39 sites in United States, Poland and 2 more
- Volunteers
- 95 people
- Sponsor
- Jazz Pharmaceuticals
Schizophrenia
Improving Negative Symptoms of Psychosis In Real-world Environments
This study will compare Cognitive Behavioral Social Skills Training-Compensatory Cognitive Training (CBSST-CCT) to a goal-focused supportive contact group to see which intervention better improves symptoms and functioning in…
- Trial name
- INSPIRE (NCT02170051)
- Testing
- CBSST-CCT, Goal focused supportive contact
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
A Study of Varenicline for Prevention of Relapse to Smoking in Patients With Schizophrenia or Bipolar Disorder
Varenicline (Chantix) is a smoking cessation treatment that was approved in 2006 by the FDA for treatment of nicotine dependence and may be particularly beneficial in smokers with schizophrenia or bipolar disorder.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Smoking
- Trial name
- SCRP (NCT00621777)
- Testing
- Varenicline
- Where
- 10 sites in United States
- Volunteers
- 247 people
- Sponsor
- Massachusetts General Hospital
Schizophrenia, PreDiabetes
Bromocriptine for Patients With Schizophrenia and Prediabetes
This is a multicenter open-label, pilot study to evaluate the safety and tolerability of bromocriptine, a dopamine D2/D3 receptor and serotonin 5-HT2C receptor agonist, as an adjunct to preexisting standard-of-care antipsychotic…
- Trial name
- NCT03575000
- Testing
- Bromocriptine
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- VA Pittsburgh Healthcare System
Schizophrenia, Schizoaffective Disorder
Mindfulness Meditation as a Rehabilitation Strategy for Persons With Schizophrenia
The purpose of this study is to develop a treatment manual for mindfulness meditation to be taught in a group format to individuals with schizophrenia who are engaged in vocational rehabilitation.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- NCT00936351
- Testing
- Mindfulness Meditation, Support Group (control)
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia
Measurement of Activity Participation for Persons With Schizophrenia Living in the Community
The purpose of the study is to develop a questionnaire on community occupational participation for persons with schizophrenia living in the community.
- Trial name
- NCT00172731
- Where
- Taiwan
- Sponsor
- National Taiwan University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.